2003
DOI: 10.1016/s0076-6879(03)64022-x
|View full text |Cite
|
Sign up to set email alerts
|

Targeted Conditional Somatic Mutagenesis in the Mouse: Temporally-Controlled Knock Out of Retinoid Receptors in Epidermal Keratinocytes

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
23
0
1

Year Published

2004
2004
2018
2018

Publication Types

Select...
5
1

Relationship

2
4

Authors

Journals

citations
Cited by 21 publications
(26 citation statements)
references
References 91 publications
2
23
0
1
Order By: Relevance
“…As expected, wild-type controls (without Cre recombinase) treated in similar manner, did not show cervical or skin alterations ( Fig. 4; Li et al, 2000;Metzger et al, 2003).…”
Section: Histological Alterations In Cervical Tissue Of Rxra L2/l2 Musupporting
confidence: 80%
See 3 more Smart Citations
“…As expected, wild-type controls (without Cre recombinase) treated in similar manner, did not show cervical or skin alterations ( Fig. 4; Li et al, 2000;Metzger et al, 2003).…”
Section: Histological Alterations In Cervical Tissue Of Rxra L2/l2 Musupporting
confidence: 80%
“…The generation of K14-Cre-ER T2 (tg/0)/RXRaL2/L2 mice and genotyping have been described previously (Li et al, 2001;Metzger et al, 2003). Transgenic animals without Tam treatment or Tam-treated K14-Cre-ER T2 (0/ 0)/RXRaL2/L2 animals were used as controls.…”
Section: Methodsmentioning
confidence: 99%
See 2 more Smart Citations
“…Compared with previous murine models of prostate carcinogenesis, our model offers major improvements that are intrinsic to our targeted spatiotemporally controlled Cre-ER T2 -mediated somatic mutagenesis (26): first, it allows us to introduce, selectively in prostatic epithelial cells, a somatic mutation targeted to any selected floxed gene at any time during the postpubertal life of the mouse; second, it allows us to modulate the number of cells in which the mutation is introduced. Our model should be particularly valuable both for exploring the molecular mechanisms underlying prostate cancer and its progression and for the development and validation of preventive and therapeutic approaches in preclinical settings.…”
Section: Discussionmentioning
confidence: 99%